SCHEMBL3367182

SCHEMBL3367182

O=C1c2ccccc2C(=O)C2OC12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 1.00
MEN1 O00255 6/20 1.00
POLB P06746 2/20 1.00
S100A4 P26447 3/20 0.55
MAPT P10636 5/20 0.50
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
LMNA P02545 2/20 0.50
MAPK1 P28482 2/20 0.50
KDM4E B2RXH2 2/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TP53 P04637 2/20 0.50
CES2 O00748 1/20 0.50
APAF1 O14727 1/20 0.50
TERT O14746 1/20 0.50
PLIN1 O60240 1/20 0.50
TDP2 O95551 1/20 0.50
S1PR4 O95977 1/20 0.50
PLA2G1B P04054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7868587 0.85 KMT2A (0.73) KMT2AMEN1POLBS100A4MAPT
SCHEMBL14567015 0.79 POLB (0.65) KMT2AMEN1POLBS100A4MAPT
SCHEMBL23457291 0.78 KMT2A (0.64) KMT2AMEN1POLBS100A4MAPT
SCHEMBL9393278 0.76 MEN1 (0.59) KMT2AMEN1POLBMAPTLMNA
SCHEMBL2130350 0.71 KMT2A (0.55) KMT2AMEN1POLBS100A4MAPT
SCHEMBL6081753 0.71 MEN1 (0.55) KMT2AMEN1POLBS100A4MAPT
SCHEMBL15245116 0.71 MEN1 (0.55) KMT2AMEN1POLBS100A4MAPT
SCHEMBL5808584 0.71 MAPT (0.56) KMT2AMEN1POLBS100A4MAPT
SCHEMBL677629 0.71 MEN1 (0.55) KMT2AMEN1POLBS100A4MAPT
SCHEMBL10344203 0.71 MEN1 (0.55) KMT2AMEN1POLBS100A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9717699-B2 Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides ADHEZION BIOMEDICAL, LLC (US) 2017-08-01 US claimed
US-20160331700-A1 Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides H.B. FULLER MEDICAL ADHESIVE TECHNOLOGIES, LLC. 2016-11-17 US claimed
US-20150283290-A1 STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES ADHEZION BIOMEDICAL, LLC (US) 2015-10-08 US claimed
WO-2002068056-A2 COMBINATION COMPRISING A 1,4-DIOXONAPHATHALENE COMPOUND AND RIBENOSIDE KS BIOMEDIX HOLDINGS PLC (GB) 2002-09-06 WO claimed
JP-3251582-B2 2002-01-28 JP claimed
EP-0570414-B1 NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION KS BIOMEDIX LTD (GB) 2000-07-05 EP claimed
US-5763479-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS KS BIOMEDIX LTD. (GB) 1998-06-09 US claimed
EP-0570414-A1 NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION KS BIOMEDIX LTD. (GB) 1993-11-24 EP claimed
WO-1992013532-A2 NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF CHRONIC INFLAMMATION CHAYEN JOSEPH (GB) 1992-08-20 WO claimed
EP-0226842-A2 Substituted 1,4-naphthalenediones, processes for their preparation and pharmaceutical compositions containing them AMERICAN CYANAMID COMPANY (US) 1987-07-01 EP claimed
EP-0149818-A2 1,4-Naphthoquinone derivatives, process for their preparation and their use as medicines Troponwerke GmbH & Co. KG (DE) 1985-07-31 EP claimed
JP-4159271-A None JP disclosed
JP-53092746-A None JP disclosed
JP-3163072-A None JP disclosed
JP-59005175-A None JP disclosed
JP-S5392746-A PREPARATION OF 2-HYDROXY-1, 4-NAPHTHOQUINONE KAWASAKI KASEI CHEM LTD 1978-08-15 JP disclosed
JP-S5346946-A PREPARATION OF 2-HYDROXY-3-HALOGENO-1,4-NAPHTHOQUINONE COPPER SALT KAWASAKI KASEI CHEM LTD 1978-04-27 JP disclosed
JP-S5315352-A PREPARATION OF 2,2'-DIHYDROXY-3,3'-BI-1,4-NAPHTHOQUINOLYL KAWASAKI KASEI CHEM LTD 1978-02-13 JP disclosed
JP-S5315350-A PREPARATION OF 2-HYDROXY-1,4-NAPHTHOQUINONE KAWASAKI KASEI CHEM LTD 1978-02-13 JP disclosed
JP-S5278859-A PREPARATION OF 2,3-EPOXY-2,3-DIHYDRO-1,4-NAPHTHOQUINONE KAWASAKI KASEI CHEM LTD 1977-07-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331700-A1 Sterilized Compositions of Cyanoacrylate Monomers and Naphthoquinone 2,3-Oxides PROC, CCNK, MMS19 KMT2A 3061/4885MEN1 699/4885POLB 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.